Company research
Nuvectis Pharma, Inc.
CIK 1875558Updated Nov 6, 2026
NVCT price & chart
Loading TradingView…
NASDAQ:NVCT on TradingView ↗About the company
Nuvectis Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement-related conditions and oncology. The Company’s pipeline includes ciprocopan (NXP100), a complement Factor B inhibitor in development for the treatment of complement-mediated diseases, and the oncology drug candidates NXP900 and NXP200, in development for the treatment of advanced cancers.
In the news
Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors ↗
Seeking Alpha
Nuvectis Pharma, Inc. (NVCT) Q3 2026 Earnings Call Transcript ↗
Nuvectis Pharma: Haisco Licensing Deal Revitalises Biotech - But No Rush To Invest Today ↗
Small-cap stocks with strong momentum grades and triple-digit YTD gains ↗
SEC disclosures
Nuvectis Pharma, Inc. files 8-K: Material Event ↗
Recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
EFFECT filing
S-3 filing
Other Events
Items 8.01, 9.01
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 35,587,000Source | 17,307,000Source | 22,376,000Source | 27,007,000Source | 18,298,000Source | 25,398,000Source | 30,148,000Source | 19,714,000Source | 31,709,000Source | 18,607,000Source | 19,185,000Source | 20,405,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 35,442,000Source | 17,169,000Source | 22,160,000Source | 26,793,000Source | 18,116,000Source | 25,130,000Source | 29,864,000Source | 19,464,000Source | 31,634,000Source | 18,533,000Source | 19,126,000Source | 19,993,000Source |
| Assets, CurrentUSD | 35,587,000Source | 17,307,000Source | 22,376,000Source | 27,007,000Source | 18,298,000Source | 25,398,000Source | 30,148,000Source | 19,714,000Source | 31,709,000Source | 18,607,000Source | 19,185,000Source | 20,405,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 11,577,000Source | 6,316,000Source | 13,294,000Source | 10,135,000Source | 5,770,000Source | 11,178,000Source | 9,194,000Source | 5,692,000Source | 13,296,000Source | 8,894,000Source | 6,984,000Source | 6,186,000Source |
| Stockholders’ equity: | ||||||||||||
| Additional Paid in CapitalUSD | 116,383,000Source | 77,988,000Source | 121,839,000Source | 101,783,000Source | 75,372,000Source | 119,957,000Source | 99,531,000Source | 72,438,000Source | 118,100,000Source | 82,958,000Source | 66,446,000Source | 46,204,000Source |
| Retained Earnings (Accumulated Deficit)USD | -92,373,000Source | -66,997,000Source | -112,757,000Source | -84,911,000Source | -62,844,000Source | -105,737,000Source | -78,577,000Source | -58,416,000Source | -99,687,000Source | -73,245,000Source | -54,245,000Source | -31,985,000Source |
| Stockholders' Equity Attributable to ParentUSD | 24,010,000Source | 10,991,000Source | 9,082,000Source | 16,872,000Source | 12,528,000Source | 14,220,000Source | 20,954,000Source | 14,022,000Source | 18,413,000Source | 9,713,000Source | 12,201,000Source | 14,219,000Source |
| Liabilities and EquityUSD | 35,587,000Source | 17,307,000Source | 22,376,000Source | 27,007,000Source | 18,298,000Source | 25,398,000Source | 30,148,000Source | 19,714,000Source | 31,709,000Source | 18,607,000Source | 19,185,000Source | 20,405,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 11,577,000Source | 6,316,000Source | 13,294,000Source | 10,135,000Source | 5,770,000Source | 11,178,000Source | 9,194,000Source | 5,692,000Source | 13,296,000Source | 8,894,000Source | 6,984,000Source | 6,186,000Source |
| Accounts Payable, CurrentUSD | 6,439,000Source | 2,261,000Source | 5,184,000Source | 4,977,000Source | 1,846,000Source | 4,695,000Source | 2,992,000Source | 1,759,000Source | 6,274,000Source | 2,498,000Source | 2,771,000Source | 2,910,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 65,000Source | 282,000Source | 92,000Source | 2,000Source | 310,000Source | 36,000Source | 865,000Source | 486,000Source | 115,000Source | 840,000Source | 415,000Source | 445,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -6,050,000Source | -5,332,000Source | -26,442,000Source | -19,000,000Source | -22,260,000Source | -19,085,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 1,850,000Source | 1,368,000Source | 6,032,000Source | 4,858,000Source | 4,705,000Source | 1,707,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -1,579,000Source | 494,000Source | 3,776,000Source | -273,000Source | -139,000Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -6,511,000Source | -4,174,000Source | -16,009,000Source | -12,247,000Source | -15,954,000Source | -13,559,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 0Source | 0Source | — | 0Source | 0Source | — |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 7,000Source | 15,505,000Source | 29,110,000Source | 11,654,000Source | 15,087,000Source | 27,810,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 35,442,000Source | 17,169,000Source | 22,160,000Source | 26,793,000Source | 25,130,000Source | 29,864,000Source | 31,634,000Source | 18,533,000Source | 19,126,000Source | 19,993,000Source |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 2,020,000Source | 1,540,000Source | 2,513,000Source | 2,982,000Source | 2,154,000Source | 1,888,000Source | 9,421,000Source | 6,929,000Source | 7,517,000Source | 6,007,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -7,462,000Source | -4,153,000Source | -7,020,000Source | -6,334,000Source | -6,050,000Source | -5,332,000Source | -26,442,000Source | -19,000,000Source | -22,260,000Source | -19,085,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -9,891,000Source | -4,153,000Source | -7,020,000Source | -6,334,000Source | -6,050,000Source | -5,332,000Source | -28,871,000Source | -19,000,000Source | -22,260,000Source | -19,085,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | — | — | 12,036,000Source | 5,289,000Source | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -7,794,000Source | -4,359,000Source | -7,197,000Source | -6,595,000Source | -6,260,000Source | -5,568,000Source | -27,574,000Source | -19,847,000Source | -22,897,000Source | -19,234,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -7,462,000Source | -4,153,000Source | -7,020,000Source | -6,334,000Source | -6,050,000Source | -5,332,000Source | -26,442,000Source | -19,000,000Source | -22,260,000Source | -19,085,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.44Source | -0.24Source | -0.3Source | -0.3Source | -0.26Source | -0.27Source | -1.32Source | -1.11Source | -1.43Source | -1.51Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.44Source | -0.24Source | -0.3Source | -0.3Source | -0.26Source | -0.27Source | -1.32Source | -1.11Source | -1.43Source | -1.51Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 22,719,057Source | 17,230,559Source | 23,475,989Source | 21,366,268Source | 23,414,475Source | 19,937,507Source | 21,812,716Source | 17,113,169Source | 15,556,655Source | 12,657,651Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 22,719,057Source | 17,230,559Source | 23,475,989Source | 21,366,268Source | 23,414,475Source | 19,937,507Source | 21,812,716Source | 17,113,169Source | 15,556,655Source | 12,657,651Source |
| Additional Financial Items | ||||||||||||
| Common Stock, Dividends, Per Share, DeclaredUSD per share | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source |
| General and Administrative ExpenseUSD | — | — | 2,020,000Source | 1,540,000Source | 2,513,000Source | 2,982,000Source | 2,154,000Source | 1,888,000Source | 9,421,000Source | 6,929,000Source | 7,517,000Source | 6,007,000Source |
| Labor and Related ExpenseUSD | — | — | — | — | — | — | — | — | 2,421,000Source | 2,091,000Source | 2,298,000Source | 1,756,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -9,891,000Source | -4,153,000Source | -7,020,000Source | -6,334,000Source | -6,050,000Source | -5,332,000Source | -28,871,000Source | -19,000,000Source | -22,260,000Source | -19,085,000Source |
| Other General and Administrative ExpenseUSD | — | — | — | — | — | — | — | — | 461,000Source | 360,000Source | 548,000Source | 687,000Source |
| Research and Development ExpenseUSD | — | — | 5,774,000Source | 2,819,000Source | 4,684,000Source | 3,613,000Source | 4,106,000Source | 3,680,000Source | 18,153,000Source | 12,918,000Source | 15,380,000Source | 13,227,000Source |
Offerings
Registration 333-298495
Registration 333-293459
Filing attachments
tm2628939d1_ex99-1.htm · 8-K · 2026-11-04
Exhibit 99.1 Nuvectis Pharma Reports Third Quarter 2026 Financial Results and Business Highlights In-licensing of ex-China rights to two potentially best-in-class compounds (NXP100 and NXP200) from Haisco Pharmaceutical Group transformed Nuvectis into a late-stage clinical development company. The Company’s lead drug candidate, ciprocopan (NXP100), a Complement Factor B inhibitor (CFBi) for once-daily oral administration, was approved in China in July 2026 for the treatment of p…
Read attachment ↗tm2623146d1_ex4-6.htm · S-3 · 2026-08-21
Exhibit 4.6 NUVECTIS PHARMA, INC. FORM OF INDENTURE Dated as of [ ], 20[ ] DEBT SECURITIES [___] Trustee CROSS REFERENCE SHEET Cross-reference sheet of provisions of the Trust Indenture Act of 1939 and this indenture* Trust Indenture Indenture Act Section Section §310 (a) 11.04(a), 16.02 (b) 11.01(f), …
Read attachment ↗tm2622125d1_ex99-1.htm · 8-K · 2026-08-04
EX-99.1 2 tm2622125d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights Completed in-licensing of ex-China rights to two potentially best-in-class compounds (NXP100 and NXP200) from Haisco Pharmaceutical Group (“Haisco”), transforming the company into a late-stage clinical development organization. The Company’s lead drug candidate, ciprocopan (NXP100), a Complement Factor B inhibitor for once-daily, or…
Read attachment ↗tm2619346d1_ex99-1.htm · 8-K · 2026-06-30
EX-99.1 4 tm2619346d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Nuvectis Pharma Announces Proposed Public Offering of Common Stock FORT LEE, NJ, June 29, 2026 - Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement-related conditions and oncology, today announced that it has commenced an underwritten public offering of its common stock. All of the shares to be sold in the offerin…
Read attachment ↗tm2619346d1_ex99-2.htm · 8-K · 2026-06-30
EX-99.2 5 tm2619346d1_ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock FORT LEE, NJ, June 29, 2026 - Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement-related conditions and oncology, today announced the pricing of its previously announced underwritten public offering of 5,000,000 shares of its common …
Read attachment ↗tm2618439d1_ex99-1.htm · 8-K · 2026-06-23
EX-99.1 2 tm2618439d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds The transaction transforms Nuvectis into a late-stage clinical development company by expanding its pipeline into complement-mediated diseases with the in-licensing of a Complement Factor B inhibitor (CFBi [NXP100]) and also enhances the oncolo…
Read attachment ↗